Risk management materials for Keytruda (pembrolizumab): Important safety information to minimise the risk of immune-related adverse reactions – Healthcare Professional Frequently Asked Questions

This document contains key information to help minimize the risk of immune-mediated side-effects such as immune-related pneumonitis, colitis, hepatitis, nephritis, endocrinopathies and other immune-related adverse reactions, providing guidance on how to monitor and manage them.

As part of the terms of the Marketing Authorisation for Keytruda, MSD are required to ensure that all Healthcare Professionals who are likely to treat patients with pembrolizumab are provided with risk minimisation materials.

 

Separately, a Patient Information Brochure and Patient Alert Card are also available, and as part of the terms of the marketing authorisation, it is required that patients are issued these.